Literature DB >> 34311478

[SARS-CoV-2 and the digestive tract - Organoids to model gastrointestinal infection].

Viktoria Hentschel1, Rüdiger Groß2, Jana Krüger1, Jan Münch2, Martin Müller1, Alexander Kleger1.   

Abstract

SARS-CoV-2 is a novel human pathogenic coronavirus whose predilection for the respiratory tract has given rise to a rapid pandemic spread via airborne particles. Organ-specific susceptibility is substantially determined by the density of cell surface expression of ACE2, which is exploited by viral spike protein as a receptor molecule to mediate adhesion and, thus, to permit internalization of the viral genome into the host cell. Based on an ample data set derived from clinical studies and case reports, evidence suggests that distinct cell populations of the digestive and olfactory-gustatory system are equally equipped with membrane-bound ACE2, rendering them "vulnerable" to SARS-CoV-2. Numerous reports on concomitant gastrointestinal complaints and laboratory abnormalities are thought to reflect a relevant degree of organ dysfunction and underscore the tropism of SARS-CoV-2 for the digestive tract. Organoids are three-dimensional in vitro replicas of organ tissue which, owing to their organotypic complex cellular composition and functional resemblance to primary cells, are particularly appreciated for basic research in the field of infectious diseases. This review specifically addresses the involvement of digestive organs by SARS-CoV-2 and outlines the significant contribution of organoid- and primary-cell culture-based models to gaining a deeper understanding of the underlying pathophysiological processes. Thieme. All rights reserved.

Entities:  

Year:  2021        PMID: 34311478     DOI: 10.1055/a-1500-8420

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  1 in total

Review 1.  [Model systems in gastroenterological research : From animal models to human organoids to the clinic].

Authors:  Frank Arnold; Alexander Kleger
Journal:  Pathologe       Date:  2021-10-08       Impact factor: 0.973

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.